A Longitudinal Study of Cognition, Proton MR Spectroscopy and Synaptic and Neuronal Pathology in Aging Wild-type and AβPPswe-PS1dE9 Mice

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Jansen, Diane ^a   Zerbi, Valerio ^a   Janssen, Carola I F ^a   Dederen, Pieter J W C ^a   Mutsaers, Martina P C ^a   Hafkemeijer, Anne ^a   Janssen, Anna Lena ^a   Nobelen, Cindy L M ^a   Veltien, Andor ^a   Asten, Jack J ^a   Heerschap, Arend ^a   Kiliaan, Amanda J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BEHAVIOR DISORDER; BODY WEIGHT; BRAIN WEIGHT; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEGENERATIVE DISEASE; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; LONGITUDINAL STUDY; MALE; MAZE TEST; MOLECULAR WEIGHT; MORRIS WATER MAZE; MOUSE; NEUROPATHOLOGY; NONHUMAN; OPEN FIELD BEHAVIOR; PROTON NUCLEAR MAGNETIC RESONANCE; SYNAPSE; TRANSGENIC MOUSE; WILD TYPE;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; COGNITION; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MAZE LEARNING; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONS; SYNAPSES;

EID: 84878050249     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063643     Document Type: Article

References (125)

1. Hardy J, Selkoe DJ, (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
2. Selkoe DJ, (2002) Alzheimer's disease is a synaptic failure. Science 298: 789-791.
3. Weller RO, Nicoll JA, (2003) Cerebral amyloid angiopathy: pathogenesis and effects on the ageing and Alzheimer brain. Neurol Res 25: 611-616.
4. Burgermeister P, Calhoun ME, Winkler DT, Jucker M, (2000) Mechanisms of cerebrovascular amyloid deposition. Lessons from mouse models. Ann N Y Acad Sci 903: 307-316.
5. Walsh DM, Selkoe DJ, (2007) A beta oligomers- a decade of discovery. J Neurochem 101: 1172-1184.
6. Larson ME, Lesne SE, (2012) Soluble Abeta oligomer production and toxicity. J Neurochem 120Suppl 1: 125-139.
7. Breteler MM, (2000) Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 21: 153-160.
8. Dosunmu R, Wu J, Basha MR, Zawia NH, (2007) Environmental and dietary risk factors in Alzheimer's disease. Expert Rev Neurother 7: 887-900.
9. Meyer JS, Terayama Y, Konno S, Akiyama H, Margishvili GM, et al. (1998) Risk factors for cerebral degenerative changes and dementia. Eur Neurol 39Suppl 1: 7-16.
10. Breteler MM, (2000) Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann N Y Acad Sci 903: 457-465.
11. Skoog I, Gustafson D, (2002) Hypertension and related factors in the etiology of Alzheimer's disease. Ann N Y Acad Sci 977: 29-36.
12. Rojo LE, Fernandez JA, Maccioni AA, Jimenez JM, Maccioni RB, (2008) Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res 39: 1-16.
13. Franceschi C, (2007) Inflammaging as a major characteristic of old people: can it be prevented or cured? Nutr Rev 65: S173-176.
14. Giunta B, Fernandez F, Nikolic WV, Obregon D, Rrapo E, et al. (2008) Inflammaging as a prodrome to Alzheimer's disease. J Neuroinflammation 5: 51.
15. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, et al. (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421.
16. Zilka N, Ferencik M, Hulin I, (2006) Neuroinflammation in Alzheimer's disease: protector or promoter? Bratisl Lek Listy 107: 374-383.
17. Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O, (2003) Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci U S A 100: 13632-13637.
18. Monje ML, Palmer T, (2003) Radiation injury and neurogenesis. Curr Opin Neurol 16: 129-134.
19. Voloboueva LA, Giffard RG, (2011) Inflammation, mitochondria, and the inhibition of adult neurogenesis. J Neurosci Res 89: 1989-1996.
20. Ross AJ, Sachdev PS, Wen W, Valenzuela MJ, Brodaty H, (2005) Cognitive correlates of 1H MRS measures in the healthy elderly brain. Brain Res Bull 66: 9-16.
21. Kantarci K, Knopman DS, Dickson DW, Parisi JE, Whitwell JL, et al. (2008) Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology 248: 210-220.
22. Jones RS, Waldman AD, (2004) 1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia. Neurol Res 26: 488-495.
23. Kantarci K, (2007) 1H magnetic resonance spectroscopy in dementia. Br J Radiol 80 Spec No 2: S146-152.
24. Schuff N, Amend D, Ezekiel F, Steinman SK, Tanabe J, et al. (1997) Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study. Neurology 49: 1513-1521.
25. Griffith HR, den Hollander JA, Okonkwo OC, O'Brien T, Watts RL, et al. (2008) Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia. Alzheimers Dement 4: 421-427.
26. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM, (2007) N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 81: 89-131.
27. Govindaraju V, Young K, Maudsley AA, (2000) Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 13: 129-153.
28. Pfefferbaum A, Adalsteinsson E, Spielman D, Sullivan EV, Lim KO, (1999) In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging. Magn Reson Med 41: 276-284.
29. Kantarci K, Petersen RC, Boeve BF, Knopman DS, Tang-Wai DF, et al. (2004) 1H MR spectroscopy in common dementias. Neurology 63: 1393-1398.
30. Huang W, Alexander GE, Chang L, Shetty HU, Krasuski JS, et al. (2001) Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study. Neurology 57: 626-632.
31. Rose SE, de Zubicaray GI, Wang D, Galloway GJ, Chalk JB, et al. (1999) A 1H MRS study of probable Alzheimer's disease and normal aging: implications for longitudinal monitoring of dementia progression. Magn Reson Imaging 17: 291-299.
32. Choi IY, Lee SP, Guilfoyle DN, Helpern JA, (2003) In vivo NMR studies of neurodegenerative diseases in transgenic and rodent models. Neurochem Res 28: 987-1001.
33. Choi JK, Dedeoglu A, Jenkins BG, (2007) Application of MRS to mouse models of neurodegenerative illness. NMR Biomed 20: 216-237.
34. Zerbi V, Jansen D, Dederen PJ, Veltien A, Hamans B, et al. (2012) Microvascular cerebral blood volume changes in aging APP(swe)/PS1 (dE9) AD mouse model: a voxel-wise approach. Brain Struct Funct. http://dx.doi.org/10.1007/s00429-012-0448-8.
35. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, et al. (2001) Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 17: 157-165.
36. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, et al. (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13: 159-170.
37. Streijger F, Oerlemans F, Ellenbroek BA, Jost CR, Wieringa B, et al. (2005) Structural and behavioural consequences of double deficiency for creatine kinases BCK and UbCKmit. Behav Brain Res 157: 219-234.
38. Hooijmans CR, Van der Zee CE, Dederen PJ, Brouwer KM, Reijmer YD, et al. (2009) DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice. Neurobiol Dis 33: 482-498.
39. de Bruin JP, Sanchez-Santed F, Heinsbroek RP, Donker A, Postmes P, (1994) A behavioural analysis of rats with damage to the medial prefrontal cortex using the Morris water maze: evidence for behavioural flexibility, but not for impaired spatial navigation. Brain Res 652: 323-333.
40. Franklin KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates. San Diego: Academic Press. xxii, [ca. 187 p.) p.
41. Cavassila S, Deval S, Huegen C, van Ormondt D, Graveron-Demilly D, (2001) Cramer-Rao bounds: an evaluation tool for quantitation. NMR Biomed 14: 278-283.
42. Jansen D, Janssen CI, Vanmierlo T, Dederen PJ, van Rooij D, et al. (2012) Cholesterol and synaptic compensatory mechanisms in Alzheimer's disease mice brain during aging. J Alzheimers Dis 31: 813-826.
43. Jahn R, Sudhof TC, (1993) Synaptic vesicle traffic: rush hour in the nerve terminal. J Neurochem 61: 12-21.
44. Gleeson JG, Lin PT, Flanagan LA, Walsh CA, (1999) Doublecortin is a microtubule-associated protein and is expressed widely by migrating neurons. Neuron 23: 257-271.
45. Francis F, Koulakoff A, Boucher D, Chafey P, Schaar B, et al. (1999) Doublecortin is a developmentally regulated, microtubule-associated protein expressed in migrating and differentiating neurons. Neuron 23: 247-256.
46. Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, et al. (1997) Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 17: 7053-7059.
47. Shukla C, Bridges LR, (1999) Regional distribution of tau, beta-amyloid and beta-amyloid precursor protein in the Alzheimer's brain: a quantitative immunolabelling study. Neuroreport 10: 3785-3789.
48. Mulder M, Koopmans G, Wassink G, Al Mansouri G, Simard ML, et al. (2007) LDL receptor deficiency results in decreased cell proliferation and presynaptic bouton density in the murine hippocampus. Neurosci Res 59: 251-256.
49. Rutten BP, Van der Kolk NM, Schafer S, van Zandvoort MA, Bayer TA, et al. (2005) Age-related loss of synaptophysin immunoreactive presynaptic boutons within the hippocampus of APP751SL, PS1M146L, and APP751SL/PS1M146L transgenic mice. Am J Pathol 167: 161-173.
50. Simon P, Dupuis R, Costentin J, (1994) Thigmotaxis as an index of anxiety in mice. Influence of dopaminergic transmissions. Behav Brain Res 61: 59-64.
51. Lalonde R, Kim HD, Fukuchi K, (2004) Exploratory activity, anxiety, and motor coordination in bigenic APPswe+PS1/DeltaE9 mice. Neurosci Lett 369: 156-161.
52. Lalonde R, Kim HD, Maxwell JA, Fukuchi K, (2005) Exploratory activity and spatial learning in 12-month-old APP(695)SWE/co+PS1/DeltaE9 mice with amyloid plaques. Neurosci Lett 390: 87-92.
53. Puolivali J, Wang J, Heikkinen T, Heikkila M, Tapiola T, et al. (2002) Hippocampal A beta 42 levels correlate with spatial memory deficit in APP and PS1 double transgenic mice. Neurobiol Dis 9: 339-347.
54. Lalonde R, Fukuchi K, Strazielle C, (2012) APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD). Neurosci Biobehav Rev 36: 1357-1375.
55. Pugh PL, Richardson JC, Bate ST, Upton N, Sunter D, (2007) Non-cognitive behaviours in an APP/PS1 transgenic model of Alzheimer's disease. Behav Brain Res 178: 18-28.
56. Grossberg GT, (2003) Diagnosis and treatment of Alzheimer's disease. J Clin Psychiatry 64Suppl 9: 3-6.
57. Patterson MB, Schnell AH, Martin RJ, Mendez MF, Smyth KA, et al. (1990) Assessment of behavioral and affective symptoms in Alzheimer's disease. J Geriatr Psychiatry Neurol 3: 21-30.
58. Vorhees CV, Williams MT, (2006) Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 1: 848-858.
59. Van Dam D, Lenders G, De Deyn PP, (2006) Effect of Morris water maze diameter on visual-spatial learning in different mouse strains. Neurobiol Learn Mem 85: 164-172.
60. Yoshiike Y, Kimura T, Yamashita S, Furudate H, Mizoroki T, et al. (2008) GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin. PLoS One 3: e3029.
61. Stover KR, Brown RE, (2012) Age-related changes in visual acuity, learning and memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease. Behav Brain Res 231: 75-85.
62. Yang SG, Wang SW, Zhao M, Zhang R, Zhou WW, et al. (2012) A peptide binding to the beta-site of APP improves spatial memory and attenuates Abeta burden in Alzheimer's disease transgenic mice. PLoS One 7: e48540.
63. Su D, Zhao Y, Xu H, Wang B, Chen X, et al. (2012) Isoflurane exposure during mid-adulthood attenuates age-related spatial memory impairment in APP/PS1 transgenic mice. PLoS One 7: e50172.
64. Lovasic L, Bauschke H, Janus C, (2005) Working memory impairment in a transgenic amyloid precursor protein TgCRND8 mouse model of Alzheimer's disease. Genes Brain Behav 4: 197-208.
65. Janus C, (2004) Search strategies used by APP transgenic mice during navigation in the Morris water maze. Learn Mem 11: 337-346.
66. Brody DL, Holtzman DM, (2006) Morris water maze search strategy analysis in PDAPP mice before and after experimental traumatic brain injury. Exp Neurol 197: 330-340.
67. Garthe A, Behr J, Kempermann G, (2009) Adult-generated hippocampal neurons allow the flexible use of spatially precise learning strategies. PLoS One 4: e5464.
68. O'Leary TP, Brown RE, (2009) Visuo-spatial learning and memory deficits on the Barnes maze in the 16-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease. Behav Brain Res 201: 120-127.
69. Taniuchi N, Niidome T, Goto Y, Akaike A, Kihara T, et al. (2007) Decreased proliferation of hippocampal progenitor cells in APPswe/PS1dE9 transgenic mice. Neuroreport 18: 1801-1805.
70. Niidome T, Taniuchi N, Akaike A, Kihara T, Sugimoto H, (2008) Differential regulation of neurogenesis in two neurogenic regions of APPswe/PS1dE9 transgenic mice. Neuroreport 19: 1361-1364.
71. Hamilton A, Holscher C, (2012) The effect of ageing on neurogenesis and oxidative stress in the APP(swe)/PS1(deltaE9) mouse model of Alzheimer's disease. Brain Res 1449: 83-93.
72. Enciu AM, Nicolescu MI, Manole CG, Muresanu DF, Popescu LM, et al. (2011) Neuroregeneration in neurodegenerative disorders. BMC Neurol 11: 75.
73. Lazarov O, Marr RA, (2010) Neurogenesis and Alzheimer's disease: at the crossroads. Exp Neurol 223: 267-281.
74. DeKosky ST, Scheff SW, Styren SD, (1996) Structural correlates of cognition in dementia: quantification and assessment of synapse change. Neurodegeneration 5: 417-421.
75. Scheff SW, Price DA, (2003) Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiol Aging 24: 1029-1046.
76. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, et al. (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572-580.
77. Hamos JE, DeGennaro LJ, Drachman DA, (1989) Synaptic loss in Alzheimer's disease and other dementias. Neurology 39: 355-361.
78. Scheff SW, Sparks DL, Price DA, (1996) Quantitative assessment of synaptic density in the outer molecular layer of the hippocampal dentate gyrus in Alzheimer's disease. Dementia 7: 226-232.
79. Scheff SW, Price DA, (1998) Synaptic density in the inner molecular layer of the hippocampal dentate gyrus in Alzheimer disease. J Neuropathol Exp Neurol 57: 1146-1153.
80. Leuba G, Savioz A, Vernay A, Carnal B, Kraftsik R, et al. (2008) Differential changes in synaptic proteins in the Alzheimer frontal cortex with marked increase in PSD-95 postsynaptic protein. J Alzheimers Dis 15: 139-151.
81. Rutten BP, Wirths O, Van de Berg WD, Lichtenthaler SF, Vehoff J, et al. (2003) No alterations of hippocampal neuronal number and synaptic bouton number in a transgenic mouse model expressing the beta-cleaved C-terminal APP fragment. Neurobiol Dis 12: 110-120.
82. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, et al. (2000) High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20: 4050-4058.
83. Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, et al. (1996) Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J Neurosci 16: 5795-5811.
84. Dong H, Martin MV, Chambers S, Csernansky JG, (2007) Spatial relationship between synapse loss and beta-amyloid deposition in Tg2576 mice. J Comp Neurol 500: 311-321.
85. Yao PJ, Bushlin I, Furukawa K, (2005) Preserved synaptic vesicle recycling in hippocampal neurons in a mouse Alzheimer's disease model. Biochem Biophys Res Commun 330: 34-38.
86. King DL, Arendash GW, (2002) Maintained synaptophysin immunoreactivity in Tg2576 transgenic mice during aging: correlations with cognitive impairment. Brain Res 926: 58-68.
87. Perneger TV, (1998) What's wrong with Bonferroni adjustments. Bmj 316: 1236-1238.
88. Siegel AF, (1990) Research Issues: Multiple Tests: Some Practical Considerations. TESOL Quarterly 24: 773-775.
89. Brown JD, Crookes G, (1990) Research Issues: The Use of Multiple t Tests in Language Research. TESOL Quarterly 24: 770-773.
90. Boncristiano S, Calhoun ME, Howard V, Bondolfi L, Kaeser SA, et al. (2005) Neocortical synaptic bouton number is maintained despite robust amyloid deposition in APP23 transgenic mice. Neurobiol Aging 26: 607-613.
91. Mukaetova-Ladinska EB, Garcia-Siera F, Hurt J, Gertz HJ, Xuereb JH, et al. (2000) Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease. Am J Pathol 157: 623-636.
92. Masliah E, Mallory M, Hansen L, DeTeresa R, Alford M, et al. (1994) Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci Lett 174: 67-72.
93. Bronfman FC, Moechars D, Van Leuven F, (2000) Acetylcholinesterase-positive fiber deafferentation and cell shrinkage in the septohippocampal pathway of aged amyloid precursor protein london mutant transgenic mice. Neurobiol Dis 7: 152-168.
94. Masliah E, Crews L, Hansen L, (2006) Synaptic remodeling during aging and in Alzheimer's disease. J Alzheimers Dis 9: 91-99.
95. Arendt T, (2001) Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization. Neuroscience 102: 723-765.
96. Kantarci K, Weigand SD, Przybelski SA, Shiung MM, Whitwell JL, et al. (2009) Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS. Neurology 72: 1519-1525.
97. Zhang B, Li M, Sun ZZ, Zhu B, Yuan L, et al. (2009) Evaluation of functional MRI markers in mild cognitive impairment. J Clin Neurosci 16: 635-641.
98. Rupsingh R, Borrie M, Smith M, Wells JL, Bartha R, (2011) Reduced hippocampal glutamate in Alzheimer disease. Neurobiol Aging 32: 802-810.
99. Watanabe T, Shiino A, Akiguchi I, (2012) Hippocampal metabolites and memory performances in patients with amnestic mild cognitive impairment and Alzheimer's disease. Neurobiol Learn Mem 97: 289-293.
100. Dedeoglu A, Choi JK, Cormier K, Kowall NW, Jenkins BG, (2004) Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res 1012: 60-65.
101. Marjanska M, Curran GL, Wengenack TM, Henry PG, Bliss RL, et al. (2005) Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc Natl Acad Sci U S A 102: 11906-11910.
102. von Kienlin M, Kunnecke B, Metzger F, Steiner G, Richards JG, et al. (2005) Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol Dis 18: 32-39.
103. Jack CR Jr, Marjanska M, Wengenack TM, Reyes DA, Curran GL, et al. (2007) Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: a new tool in Alzheimer's disease research. Neuroscientist 13: 38-48.
104. Oberg J, Spenger C, Wang FH, Andersson A, Westman E, et al. (2008) Age related changes in brain metabolites observed by 1H MRS in APP/PS1 mice. Neurobiol Aging 29: 1423-1433.
105. Mlynarik V, Cacquevel M, Sun-Reimer L, Janssens S, Cudalbu C, et al. (2012) Proton and phosphorus magnetic resonance spectroscopy of a mouse model of Alzheimer's disease. J Alzheimers Dis 31Suppl 3: S87-99.
106. Woo DC, Lee SH, Lee DW, Kim SY, Kim GY, et al. (2010) Regional metabolic alteration of Alzheimer's disease in mouse brain expressing mutant human APP-PS1 by 1H HR-MAS. Behav Brain Res 211: 125-131.
107. Xu W, Zhan Y, Huang W, Wang X, Zhang S, et al. (2010) Reduction of hippocampal N-acetyl aspartate level in aged APP(Swe)/PS1(dE9) transgenic mice is associated with degeneration of CA3 pyramidal neurons. J Neurosci Res 88: 3155-3160.
108. Jessen F, Gur O, Block W, Ende G, Frolich L, et al. (2009) A multicenter (1)H-MRS study of the medial temporal lobe in AD and MCI. Neurology 72: 1735-1740.
109. Kantarci K, Weigand SD, Petersen RC, Boeve BF, Knopman DS, et al. (2007) Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 28: 1330-1339.
110. Satlin A, Bodick N, Offen WW, Renshaw PF, (1997) Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist. Am J Psychiatry 154: 1459-1461.
111. Frederick B, Satlin A, Wald LL, Hennen J, Bodick N, et al. (2002) Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline. Am J Geriatr Psychiatry 10: 81-88.
112. Chen SQ, Cai Q, Shen YY, Wang PJ, Teng GJ, et al. (2012) Age-related changes in brain metabolites and cognitive function in APP/PS1 transgenic mice. Behav Brain Res 235: 1-6.
113. Chen SQ, Wang PJ, Ten GJ, Zhan W, Li MH, et al. (2009) Role of myo-inositol by magnetic resonance spectroscopy in early diagnosis of Alzheimer's disease in APP/PS1 transgenic mice. Dement Geriatr Cogn Disord 28: 558-566.
114. Ruan L, Kang Z, Pei G, Le Y, (2009) Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimer's disease. Curr Alzheimer Res 6: 531-540.
115. Machova E, Rudajev V, Smyckova H, Koivisto H, Tanila H, et al. (2010) Functional cholinergic damage develops with amyloid accumulation in young adult APPswe/PS1dE9 transgenic mice. Neurobiol Dis 38: 27-35.
116. Verret L, Jankowsky JL, Xu GM, Borchelt DR, Rampon C, (2007) Alzheimer's-type amyloidosis in transgenic mice impairs survival of newborn neurons derived from adult hippocampal neurogenesis. J Neurosci 27: 6771-6780.
117. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, et al. (2006) Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 24: 516-524.
118. Hasselmo ME, (2006) The role of acetylcholine in learning and memory. Curr Opin Neurobiol 16: 710-715.
119. Deng W, Aimone JB, Gage FH, (2010) New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory? Nat Rev Neurosci 11: 339-350.
120. Zerbi V, Kleinnijenhuis M, Fang X, Jansen D, Veltien A, et al. (2012) Gray and white matter degeneration revealed by diffusion in an Alzheimer mouse model. Neurobiol Aging 34: 1440-1450.
121. Palop JJ, Mucke L, (2010) Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci 13: 812-818.
122. Szapacs ME, Numis AL, Andrews AM, (2004) Late onset loss of hippocampal 5-HT and NE is accompanied by increases in BDNF protein expression in mice co-expressing mutant APP and PS1. Neurobiol Dis 16: 572-580.
123. Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, et al. (2005) Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 18: 602-617.
124. Hooijmans CR, Graven C, Dederen PJ, Tanila H, van Groen T, et al. (2007) Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP/PS1 mice. Brain Res 1181: 93-103.
125. Hooijmans CR, Rutters F, Dederen PJ, Gambarota G, Veltien A, et al. (2007) Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched Typical Western Diet (TWD). Neurobiol Dis 28: 16-29.